Company / R&D Expense
Tandem Diabetes Care R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$193.1M
FY2025
5-year range
$45.2M / $198.9M
FY2021-FY2025
Trend
-2.9%
vs FY2024
Sector context
#39 of 110
Health Care
What the data says
At $193M, Tandem Diabetes Care's r&d expense ranks #39 of 110 in the Health Care sector. Improved from $170M to $193M over the past 2 years.
Based on SEC 10-K filings.
$193M in FY2025 with a 5-year CAGR of +45.9%.
Improved from $170M to $193M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +44.8%
- 5-Year CAGR
- +45.9%
- 10-Year CAGR
- -
Sector benchmark
#39 of 110 in Health CareTop 35% of 110This company $193.1M Sector average $298.2M
▼
-35.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +45.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 2.9% year-over-year.
- Ranks #39 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $193.1M | -2.9% |
| FY2024 | $198.9M | +17.2% |
| FY2023 | $169.7M | +166.9% |
| FY2022 | $63.6M | +40.7% |
| FY2021 | $45.2M | +54.6% |
| FY2020 | $29.2M | +41.5% |
| FY2019 | $20.7M | +9.8% |
| FY2018 | $18.8M | +10.9% |
| FY2017 | $17.0M | -9.8% |
| FY2016 | $18.8M | +10.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026